Xeriant, Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Apr 23, 2020 and accepted by EDGAR at Apr 23, 2020, 17:25 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2019-07-01 to 2019-09-30 | $6.3k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$17.7k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-07-01 to 2019-09-30 | −$1.2k | us-gaap:InterestExpense |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$19.2k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2019-07-01 to 2019-09-30 | −$19.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2019-09-30 | $169.8k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $169.8k | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $169.8k | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $272.7k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $272.7k | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-09-30 | −$102.9k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001477932-20-002154. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.